Extracellular Vesicle Therapeutics for Regenerative Medicine (ExTReMe)

Key Facts

Status: Open

Posted date: June 27, 2025

Opportunity ID: 359866

Opportunity number: FOR-TR-27-002

Opportunity category: Discretionary

Agency name: National Institutes of Health

Agency code: HHS-NIH11

Award floor: $0

Award ceiling: $0

Cost sharing required: No

Funding Instrument Types
  • Cooperative Agreement
Category of Funding Activity
  • Health
Eligible Applicants
  • County governments
  • For-profit organizations other than small businesses
  • Independent school districts
  • Native American tribal governments (Federally recognized)
  • Native American tribal organizations (other than Federally recognized tribal governments)
  • Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education
  • Private institutions of higher education
  • Public and State controlled institutions of higher education
  • Public housing authorities/Indian housing authorities
  • Small businesses
  • State governments
Tools
Categories (use these for quoted searches)
  • agency_code:hhs_nih11
  • category_of_funding_activity:health
  • cost_sharing_or_matching_requirement:false
  • eligible_applicants:county_governments
  • eligible_applicants:for_profit_organizations_other_than_small_businesses
  • eligible_applicants:independent_school_districts
  • eligible_applicants:native_american_tribal_governments_federally_recognized
  • eligible_applicants:native_american_tribal_organizations_other_than_federally_recognized_tribal_governments
  • eligible_applicants:nonprofits_having_a_501_c_3_status_with_the_irs_other_than_institutions_of_higher_education
  • eligible_applicants:private_institutions_of_higher_education
  • eligible_applicants:public_and_state_controlled_institutions_of_higher_education
  • eligible_applicants:public_housing_authoritiesindian_housing_authorities
  • eligible_applicants:small_businesses
  • eligible_applicants:state_governments
  • funding_instrument_type:cooperative_agreement
  • opportunity_category:discretionary
  • status:open
Description

The National Center for Advancing Translational Science (NCATS) seeks to advance its mission by advancing research on extracellular vesicles (EVs) and their use as therapeutics in the field of regenerative medicine.The main objective of this program, Extracellular Vesicle Therapeutics for Regenerative Medicine (ExTReMe), is to support the translation of EV-based therapeutics in regenerative medicine. EVs, like exosomes and microvesicles, are crucial mediators of intercellular communication, carrying diverse cargo like proteins, nucleic acids, and lipids. In regenerative medicine, EVs play a significant role by influencing cellular behaviors during tissue repair and regeneration. Due to their natural function in intercellular communication, EVs represent a novel, cell-free, therapeutic tool. EVs can be further engineered to deliver therapeutic agents or modulate signaling pathways involved in repair/regeneration.Areas of interest for ExTReMe could include, but are not limited to:direct EV therapy (stem cell-isolated EVs produced under GLP conditions, and stored as off-the-shelf therapies);designer EVs (personalized to the individual patient’s needs).Grant authorities that allow the National Center for Advancing Translational Science (NCATS) to forecast this opportunity are as follows: 42 U.S. Code § 287a - Cures Acceleration Network

Extracellular Vesicle Therapeutics for Regenerative Medicine (ExTReMe)
The National Center for Advancing Translational Science (NCATS) seeks to advance its mission by advancing research on extracellular vesicles (EVs) and their use as therapeutics in the field of regenerative medicine.The main objective of this program, Extracellular Vesicle Therapeutics for Regenerative Medicine (ExTReMe), is to support the translation of EV-based therapeutics in regenerative medicine. EVs, like exosomes and microvesicles, are crucial mediators of intercellular communication, carrying diverse cargo like proteins, nucleic acids, and lipids. In regenerative medicine, EVs play a significant role by influencing cellular behaviors during tissue repair and regeneration. Due to their natural function in intercellular communication, EVs represent a novel, cell-free, therapeutic tool. EVs can be further engineered to deliver therapeutic agents or modulate signaling pathways involved in repair/regeneration.Areas of interest for ExTReMe could include, but are not limited to:direct EV therapy (stem cell-isolated EVs produced under GLP conditions, and stored as off-the-shelf therapies);designer EVs (personalized to the individual patient’s needs).Grant authorities that allow the National Center for Advancing Translational Science (NCATS) to forecast this opportunity are as follows: 42 U.S. Code § 287a - Cures Acceleration Network
Extracellular Vesicle Therapeutics for Regenerative Medicine (ExTReMe)
Open
National Institutes of Health
Health
Cooperative Agreement
State governments
County governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For-profit organizations other than small businesses
Small businesses
2025-06-27